📜 What This Document Is

This is a prospectus (Form 424B3) for CapsoVision, Inc. (CV). Its sole job is to allow certain existing investors to resell 2,867,089 shares of the company's common stock to the public.

👉 In simple terms: The company already sold these shares privately to investors. Now, those investors have the right to sell them on the open market. This filing is the legal paperwork that makes that possible. CapsoVision itself will not receive any money from these sales.

🏢 What The Company Does

CapsoVision is a medical device company. It develops and sells advanced imaging systems for the gastrointestinal (GI) tract, like colonoscopies. Their flagship product is likely the CapsoCam, a capsule endoscope you swallow to take pictures inside your body.

👉 Why it matters: As a smaller, specialized medical tech firm, it's in a capital-intensive industry that requires constant innovation and regulatory approval. This context explains why they raised money privately (the "PIPE" transaction) and why these investors might now want to sell.

🤝 The Share Resale Deal

• What's Being Sold: 2,867,089 shares of common stock, called the "PIPE Shares."
• Where They Came From: A private placement ( PIPE = Private Investment in Public Equity) completed on March 16, 2026.
• The Deal: The company sold these shares directly to a group of "accredited investors" (wealthy individuals or institutions) under specific exemptions that let them avoid a full public registration at the time.
• The Catch: As part of that deal, the company signed a "Registration Rights Agreement," promising to later file paperwork (this prospectus!) so the investors could publicly sell their shares if they wanted to.

📊 The Numbers At A Glance

• Shares Being Registered: 2,867,089
• Shares Outstanding After This Resale: 49,838,867 (this number doesn't change; it just shows the total pie).
• Potential Future Dilution: There are also:
  • 168,898 shares from warrants (average exercise price: $6.25)
  • 2,128,731 shares from stock options (average exercise price: $2.18)
  • 24,270 shares from restricted stock units
  • 5,427,163 shares reserved for future employee grants

⚠️ Key Risk Factors

The filing lists many risks. Here are the most critical ones for a potential investor to understand:

• Customer Concentration: The business may depend heavily on a few key customers or suppliers. Losing one could hurt revenue.
• Regulatory Hurdles: As a medical device company, CapsoVision's success depends on getting and keeping approvals from the FDA and other regulators. This process is slow, expensive, and uncertain.
• Profitability & Cash: The company has a history of losses and may need more money to fund operations, which could mean selling more shares (diluting you) or taking on debt.
• Competition: The GI imaging field has established competitors. New tech or competitors could hurt their market share.
• Supply Chain & Disasters: The company is based in Saratoga, California, an area prone to earthquakes and wildfires. They also rely on third-party manufacturers. A disaster could severely disrupt business, and they have no earthquake insurance.

👤 The Selling Stockholders

The document lists the specific investors (names are omitted here for privacy) who are selling their shares. They paid for these shares in the private deal on March 16, 2026. They are the ones who will get the cash from any public sale, not the company.

🔮 What's Next & Company Status

• Company Status: CapsoVision is an "Emerging Growth Company" and a "Smaller Reporting Company." This means it has reduced disclosure requirements (e.g., it only needs two years of audited financials and has exemptions from some executive compensation disclosures). This status lasts for up to five years or until it hits certain size thresholds.
• Financial Policy: The company has never paid a dividend and doesn't plan to. Any earnings will be reinvested into the business.
• Strategy: The filing doesn't outline new strategy. The registration of these shares is a contractual obligation from their March 2026 financing deal.

⚖️ Big Picture

• 👍 Strengths: Operates in the growing field of minimally invasive medical diagnostics. Has commercialized a product. Successfully raised capital from private investors in March 2026.
• ⚠️ Risks: A high-risk, high-reward profile typical of small-cap medical device companies. Faces regulatory, commercial, and financial execution risks. The share resale itself adds a small amount of selling pressure to the market.

🧠 The Analogy

Imagine a small, promising startup (CapsoVision) that needed cash. Instead of an IPO, it sold a slice of itself directly to a handful of wealthy backers (the PIPE deal). Now, those backers want the freedom to sell that slice to anyone on the open market. This filing is the company holding the door open for them to do just that. It's a routine step after a private funding round, but it reminds us that the company's value is now being tested daily by the public market.

🧩 Final Takeaway

This filing is a liquidity event for existing investors, not a new capital raise for CapsoVision. It highlights the company's position as a small, early-stage medical device player navigating the classic challenges of funding, regulation, and scaling. The real story for investors isn't in these being sold shares, but in whether the underlying business can deliver on its technology's promise.